This review is a summary of evidence in support of tofacitinib citrate (XELJANZ®) in the treatment of rheumatoid arthritis. Tofacitinib is an orally-administered targeted immunomodulator and disease-modifying therapy that inhibits the Janus kinase (JAK) family of kinases. In Australia, tofacitinib is indicated for the treatment of the signs and symptoms of moderate-to-severe active rheumatoid arthritis in adults who have had an inadequate response or are intolerant to methotrexate.
Independent expert commentary provided by Associate Professor Paul Bird, who is a Rheumatologist in Sydney, Australia.
He is Associate Professor at the Department of Medicine, University Of New South Wales.
Please login below to download this issue (PDF)